Aicure

Aicure

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments.

Based in New York, USA, AiCure was founded by Adam Hanina and Laura Shafner in 2010. AiCure is a data-analytics company that uses artificial intelligence to understand how patients respond and comply with medication treatments. The AI assists with patient/ provider decision-making and records patient outcomes. Additionally, AiCure developed a patented facial recognition and motion-sensing application; accessible by a front-facing smartphone camera, that tracks real-time medication compliance and ingestion. AiCure is funded by the National Institutes of Health (NIH) as well as investors. AiCure has over 65 patents and has expanded globally to over 30 countries.

AiCure uses artificial intelligence to see, hear, and understand how patients respond to treatment. Additionally, AiCure developed the aforementioned IMA, an interactive medical assistant, available via a smartphone with camera, to assist patients and ensure they receive treatment or follow medication compliance routine.

COVID-19 Response and Contribution:

COVID-19 is changing the way the industry thinks about preserving clinical trials while ensuring patient safety. AiCure enables continuity by providing remote and direct patient communication and engagement, ensuring assessments, medication adherence, virtual registration, training, and payments. Sites can continue to provide care and stay closely connected to their patients with a trusted provider of direct site and patient communication for a decade. AiCure is working with sites to maintain their patient relationship via video chat (telehealth) in a HIPAA and GDPR compliant manner while maintaining patient safety and privacy.

Timeline

April 28, 2020

AiCure Launches Platform to Remotely Capture Digital Biomarkers in Clinical Trials

November 8, 2019

AiCure has a post-money valuation in the range of $100M to $500M as of Nov 8, 2019 according to PrivCo.

November 7, 2019

Their latest funding was raised on Nov 7, 2019 from a Series C round. AiCure is funded by 11 investors. Singtel Innov8 and New Leaf Venture Partners are the most recent investors.

November 2019

Aicure raises a $24,500,000 series C round from Asahi Kasei, New Leaf Venture Partners, SingTel Innov8, Biomatics Capital Partners, Silicon Valley Bank, Accelmed Growth Partners, Tribeca Venture Partners, Palisades Growth Capital, Springrock Ventures, Baird Capital and Pritzker Group Venture Capital.

November 2017

Aicure raises a $15,000,000 series B round from New Leaf Venture Partners, Biomatics Capital Partners, Tribeca Venture Partners, Pritzker Group and Baird Capital.

January 2015

Aicure raises a $12,300,000 series A round from Biomatics Capital Partners, New Leaf Venture Partners, Pritzker Group and Tribeca Venture Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Edward Ikeguchi

Chief Executive Officer

Lei Guan

Chief Technology Officer

Rich Christie

Chief Development Officer

Further reading

Title
Author
Link
Type
Date

AI-Enabled Drug Discovery & Clinical Trials Market 2020-2026 Increasing Drug Development Expenditure By Major Key Players: AiCure, LLC, Berkeley Lights, Inc., CytoReason, Exscientia Limited, Mind the Byte, Symphony Innovation, LLC - 3w Market News Reports

Web

June 22, 2020

AiCure | NIH SBIR/STTR

Web

August, 2016

AiCure's strategy of providing data for life sciences reinforced by record economic momentum

AiCure

Web

January 14, 2020

New Research Sheds Light on Intentional Non-adherence in Clinical Trials

Web

June 15, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.